Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Shares Issued (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Shares Issued for 4 consecutive years, with $3.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued fell 16.09% to $3.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $12.4 million, a 106.1% increase, with the full-year FY2024 number at $11.2 million, up 3521.61% from a year prior.
  • Shares Issued was $3.6 million for Q3 2025 at Centessa Pharmaceuticals, up from $1.7 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $5.3 million in Q4 2024 to a low of -$405000.0 in Q3 2022.
  • A 4-year average of $1.4 million and a median of $802000.0 in 2024 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: tumbled 82.86% in 2023, then skyrocketed 6583.33% in 2024.
  • Centessa Pharmaceuticals' Shares Issued stood at -$405000.0 in 2022, then skyrocketed by 129.14% to $118000.0 in 2023, then soared by 4427.12% to $5.3 million in 2024, then crashed by 33.32% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Shares Issued are $3.6 million (Q3 2025), $1.7 million (Q2 2025), and $1.8 million (Q1 2025).